Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
Clinical trial NCT07542678 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07542678
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2028-04-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.